Whoop is opening its Advanced Labs blood-testing service to non-members and adding Grail's Galleri multi-cancer early detection test, expanding access to a blood-based screen designed to detect signals linked to more than 50 cancer types. The company says testing starts at about $150, with 8 in 10 users seeing a “meaningful” health finding and more than half receiving results warranting further follow-up.

Why It Matters To Oncology

• Galleri brings an MCED option into a consumer-facing digital health platform, potentially widening the front door for earlier cancer signal detection.

• For clinicians and drug discovery stakeholders, broader uptake of blood-based screening could increase downstream diagnostic workups, earlier referrals and future real-world data generation around pre-diagnostic cancer detection.

• Results will be delivered through the Whoop app, pairing testing with clinician review and educational resources rather than a direct-to-consumer result alone.

The Financials

• Advanced Labs is powered by Quest Diagnostics and will offer Galleri at nearly 2,000 Quest locations across the U.S.

• Testing starts at around $150, positioning the service below concierge medicine or executive-physical channels cited by Whoop's leadership.

• CEO Will Ahmed said recently that Whoop is on track to go public in roughly 18 months, while the company plans to hire 600 people this year and lease 107,000 square feet near its Boston headquarters.

What They're Saying

• Chief Medical Officer Ami Bhatt said the goal is to make comprehensive testing more accessible so people can better understand their health and make earlier, more informed decisions.

• Whoop says its lab service combines clinician-reviewed results, AI-powered insights and personalized recommendations across cardiovascular, metabolic, hormonal and inflammatory health.

• The company is framing the expansion as part of a broader health platform build-out, not just a wearables add-on.

What's Next

• Watch whether oncologists and primary care clinicians see meaningful referral volume or false-positive management burdens as MCED access broadens.

• Whoop's Connected Care push for eligible Medicare beneficiaries suggests a strategy to move from wellness tracking toward reimbursable, longitudinal care services.

• For oncology innovators, the key question is whether consumer-facing platforms can help normalize blood-based early detection and create scalable pathways into confirmatory diagnostics and intervention.